Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2556 | Eburicoic acid |
| 1. Eburicoic acid has significant anti-liver cancer effects and more distinctive mechanisms. 2. Eburicoic acid and TR2 protect the liver from CCl4-induced hepatic damage via antioxidant and anti-inflammatory mechanisms. 3. Eburicoic acid and TR2 have anti-inflammatory activity, the mechanism is related to the decrease of inflammatory cytokines and an increase of antioxidant enzyme activity. | |
| BCN2560 | Cirsilineol |
| 1. Cirsilineol might be potentially useful for treating T-cell-mediated human inflammatory bowel diseases. 2. Cirsilineol has anti-proliferative activity against cancer cells by the induction of apoptosis via the mitochondrial pathway. | |
| BCN2570 | Tenacissoside H |
| Tenacissoside H has antitumor activity on esophageal cancer through arresting cell cycle and regulating PI3K/Akt-NF-κB transduction cascade. | |
| BCN2582 | Prosapogenin A |
| Prosapogenin A has anti-obesity, and immunomodulating effects, it exhibits cytotoxic activity against the cancer cell line K562 in vitro. | |
| BCN2586 | Plumbagin |
| Plumbagin, a potential natural FOXM1 inhibitor, has anticancer, and anti-fibrotic activies, it inactivates the NF-κB/TLR-4 pathway that is associated with inflammatory reactions, thereby mitigating liver fibrosis. Plumbagin offers significant protective role against DEX-induced cellular damage via regulating oxidative stress, apoptosis, and osteogenic markers. | |
